

<h3>Bibliografía</h3>

    <ol>
        <li>Favarolo E J, Funk DMA, Lippi G. Pre-analytical variables in coagulation testing associated with diagnostic errors in hemostasis. Lab Medicine 2012;43:1-10.</li>
        <li>Lima-Oliveira G, Salvagno GL, Lippi G, Danese E, Gelati M, Montagnana M, et al. Could light meal jeopardize laboratory coagulation tests? Biochem Med (Zagreb) 2014;24:343-9.</li>
        <li>Lippi G, Salvagno GL, Lima-Oliveira G, Danese E, Favarolo EJ, Guidi GC. Influence of posture on routine hemostasis testing. Blood Coagul Fibrinolysis 2015;26:716-9.</li>
        <li>Lima-Oliveira G, Salvagno GL, Lippi G, Montagnana M, Scartezini M, Picheth G, et al. Elimination of the venous stasis error for routine coagulation testing by transillumination. Clin Chim Acta 2011;412:1482-4.</li>
        <li>Lima-Oliveira G, Salvagno GL, Danese E, Favaloro EJ, Guidi GC, Lippi G. Sodium citrate blood contamination by K2-ethylenediaminetetraacetic acid (EDTA): impact on routine coagulation testing. Int J Lab Hematol 2015;37:403-9.</li>
        <li>Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med 2017;377:1177-87.</li>
        <li>Moll S. Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis 2015;349:367-78.</li>
        <li>Schuster V, Hügle B, Tefs K. Plasminogen deficiency. J Thromb Haemost 2007;5:2315-22.</li>
        <li>Bugge TH1, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995;9:794-807.</li>
        <li>Lethagen S. Desmopressin (DDAVP) and hemostasis. Ann Hematol 1994;69:173-80.</li> 
        <li>Miles LA, Plow EF, Donnelly KJ, Hougie C, Griffin JH. A Bleeding Disorder Due to Deficiency of a2-Antiplasmin. Blood 1982;59:1246-51.</li>
        <li>Carpenter SL, Mathew P. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 2008;14:1250-4.</li>
        <li>Tofler GH, Massaro J, O’Donnell CJ, Wilson PWF, Vasan RS, Sutherland PA, et al. Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study. Thromb Res 2016;140:30-35.</li>
        <li>Andreasen PA. PAI-1-a potential therapeutic target in cancer. Curr Drug Targets 2007;8:1030-41.</li>
        <li>Wang X, Smith PL, Hsu MY, Tamasi JA, Bird E, Schumacher WA. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis. J Thromb Thrombolysis 2007;23:41-9.</li>
        <li>Mosnier LO, Lisman T, van den Berg HM, Nieuwenhuis HK, Meijers JC, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001;86:1035-9.
        <li>Colucci M, Incampo F, Cannavò A, Menegatti M, Siboni SM, Zaccaria F, et al. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway. J Thromb Haemost 2016;14:1603-14.</li>
        <li>Linkins LA, Takach Lapner S. Review of D-dimer testing: Good, Bad, and Ugly. Int J Lab Hematol 2017;39:98-103.</li>
        <li>Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with metaanalysis and trial sequential analysis. Anaesthesia 2017;72:519-531.</li>
        <li>Hemker HC, Al dieri R, De Smedi E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006;96:553-61.</li>
    </ol>